Spinraza™

What is Spinraza™?

Spinraza™ (nusinersen) is the first treatment approved to treat SMA in Europe.

Spinraza™ is intrathecal applied medicine that is designed to increase SMN protein levels in the central nervous system (CNS). This SMN-enhancing therapy is a antisense oligonucleotide that targets the SMN2 gene and helps to increase the amount of stable SMN protein made by this gene.

At a glance

Spinraza™ facts

  • Spinraza is approved for all ages and types of SMA in many European countries
  • Access to Spinraza varies
  • Spinraza is given via an intrathecal (IT) injection, which is an injection directly into the cerebrospinal fluid through the lower back. Individuals receive four “loading doses” within the first 2 months of treatment. Once those loading doses are completed, they receive a maintenance dose every 4 months for the duration of the individual’s life.
  • Spinraza is an antisense oligonucleotide.
  • Spinraza was tested in multi-centre clinical trials in a number of infants and children.
  • After the pre-clinical work and early clinical testing was complete, Ionis Pharmaceuticals partnered with Biogen to test Spinraza in clinical trials and bring it to the markets.
This website stores essential cookies to enable important site functionality, and analytics cookies so we can understand usage and improve the service. Read our privacy policy